Nuformix Expands Licensing Agreement with Newsummit Biopharma for cancer supportive care product

Cambridge, UK - 27th November 2018

Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, announces it has expanded its licensing agreement with Newsummit Biopharma (“NSB”), its Chinese licensing partner for NXP001, which is in development for cancer supportive care.

Download News

Back to all News